• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同的BCR/Abl蛋白抑制模式作为慢性粒细胞白血病细胞适应能量限制的共同特征。

Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction.

作者信息

Bono Silvia, Lulli Matteo, D'Agostino Vito Giuseppe, Di Gesualdo Federico, Loffredo Rosa, Cipolleschi Maria Grazia, Provenzani Alessandro, Rovida Elisabetta, Dello Sbarba Persio

机构信息

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", Università degli Studi di Firenze, Florence, Italy.

Centre For Integrative Biology (CIBIO), Università degli Studi di Trento, Trento, Italy.

出版信息

Oncotarget. 2016 Dec 20;7(51):84810-84825. doi: 10.18632/oncotarget.13319.

DOI:10.18632/oncotarget.13319
PMID:27852045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5356700/
Abstract

BCR/Abl protein drives the onset and progression of Chronic Myeloid Leukemia (CML). We previously showed that BCR/Abl protein is suppressed in low oxygen, where viable cells retain stem cell potential. This study addressed the regulation of BCR/Abl protein expression under oxygen or glucose shortage, characteristic of the in vivo environment where cells resistant to tyrosine kinase inhibitors (TKi) persist. We investigated, at transcriptional, translational and post-translational level, the mechanisms involved in BCR/Abl suppression in K562 and KCL22 CML cells. BCR/abl mRNA steady-state analysis and ChIP-qPCR on BCR promoter revealed that BCR/abl transcriptional activity is reduced in K562 cells under oxygen shortage. The SUnSET assay showed an overall reduction of protein synthesis under oxygen/glucose shortage in both cell lines. However, only low oxygen decreased polysome-associated BCR/abl mRNA significantly in KCL22 cells, suggesting a decreased BCR/Abl translation. The proteasome inhibitor MG132 or the pan-caspase inhibitor z-VAD-fmk extended BCR/Abl expression under oxygen/glucose shortage in K562 cells. Glucose shortage induced autophagy-dependent BCR/Abl protein degradation in KCL22 cells. Overall, our results showed that energy restriction induces different cell-specific BCR/Abl protein suppression patterns, which represent a converging route to TKi-resistance of CML cells. Thus, the interference with BCR/Abl expression in environment-adapted CML cells may become a useful implement to current therapy.

摘要

BCR/Abl蛋白驱动慢性髓性白血病(CML)的发生和发展。我们之前发现,在低氧环境中BCR/Abl蛋白受到抑制,此时存活的细胞保留着干细胞潜能。本研究探讨了在氧气或葡萄糖缺乏的情况下BCR/Abl蛋白表达的调控,这种情况是体内环境的特征,在该环境中对酪氨酸激酶抑制剂(TKi)耐药的细胞持续存在。我们在转录、翻译和翻译后水平研究了K562和KCL22慢性髓性白血病细胞中BCR/Abl抑制所涉及的机制。BCR/abl mRNA稳态分析以及对BCR启动子的ChIP-qPCR显示,在低氧条件下K562细胞中BCR/abl的转录活性降低。SUnSET分析表明,在两种细胞系中,氧气/葡萄糖缺乏时蛋白质合成总体减少。然而,只有低氧显著降低了KCL22细胞中与多核糖体相关的BCR/abl mRNA,提示BCR/Abl翻译减少。蛋白酶体抑制剂MG132或泛半胱天冬酶抑制剂z-VAD-fmk在氧气/葡萄糖缺乏时延长了K562细胞中BCR/Abl的表达。葡萄糖缺乏诱导KCL22细胞中自噬依赖性的BCR/Abl蛋白降解。总体而言,我们的结果表明能量限制诱导了不同的细胞特异性BCR/Abl蛋白抑制模式,这代表了慢性髓性白血病细胞对TKi耐药的一条共同途径。因此,干扰适应环境的慢性髓性白血病细胞中BCR/Abl的表达可能成为当前治疗的一种有用手段。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/fcc27a66c6c0/oncotarget-07-84810-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/427929d9448c/oncotarget-07-84810-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/fbc1d190f513/oncotarget-07-84810-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/92e8f8656c2a/oncotarget-07-84810-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/4e3d63cd28a1/oncotarget-07-84810-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/a10caf1addca/oncotarget-07-84810-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/dd295be30cd7/oncotarget-07-84810-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/b679ce7acb1e/oncotarget-07-84810-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/fcc27a66c6c0/oncotarget-07-84810-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/427929d9448c/oncotarget-07-84810-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/fbc1d190f513/oncotarget-07-84810-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/92e8f8656c2a/oncotarget-07-84810-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/4e3d63cd28a1/oncotarget-07-84810-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/a10caf1addca/oncotarget-07-84810-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/dd295be30cd7/oncotarget-07-84810-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/b679ce7acb1e/oncotarget-07-84810-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4de/5356700/fcc27a66c6c0/oncotarget-07-84810-g008.jpg

相似文献

1
Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction.不同的BCR/Abl蛋白抑制模式作为慢性粒细胞白血病细胞适应能量限制的共同特征。
Oncotarget. 2016 Dec 20;7(51):84810-84825. doi: 10.18632/oncotarget.13319.
2
Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.靶向刺猬信号通路和自噬可克服BCR-ABL阳性慢性髓性白血病的耐药性。
Autophagy. 2015;11(2):355-72. doi: 10.4161/15548627.2014.994368.
3
ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.由BCR-ABL调节的凋亡微小RNA表达与慢性粒细胞白血病进展及伊马替尼耐药相关。
Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):47-55. doi: 10.1016/j.bcmd.2014.02.008. Epub 2014 Mar 11.
4
Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells. Sonic hedgehog 信号通路调节人慢性髓系白血病细胞中 Bcr-Abl 的表达。
Biomed Pharmacother. 2012 Jul;66(5):378-83. doi: 10.1016/j.biopha.2011.12.008. Epub 2012 Feb 16.
5
Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose.在缺乏葡萄糖的情况下,甲磺酸伊马替尼可增强慢性髓性白血病干细胞的潜能维持。
Stem Cell Res. 2018 Apr;28:33-38. doi: 10.1016/j.scr.2018.01.038. Epub 2018 Jan 31.
6
Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.雷公藤甲素抑制Bcr-Abl转录并诱导携带T315I突变的STI571耐药慢性粒细胞白血病细胞凋亡。
Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.
7
Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.Polo-like 激酶 1(Plk1)作为慢性髓性白血病的一个新的药物靶点:用 Plk1 抑制剂 BI 2536 克服伊马替尼耐药性。
Cancer Res. 2010 Feb 15;70(4):1513-23. doi: 10.1158/0008-5472.CAN-09-2181. Epub 2010 Feb 9.
8
Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.K562 细胞的单细胞分析:对伊马替尼耐药的亚群细胞呈黏附状态,BCR-ABL mRNA 和蛋白表达上调。
Exp Hematol. 2014 Mar;42(3):183-191.e5. doi: 10.1016/j.exphem.2013.11.006. Epub 2013 Nov 20.
9
Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis.脂质体硼替佐米通过破坏Sp1-BCR/ABL轴对慢性髓性白血病具有活性。
Oncotarget. 2016 Jun 14;7(24):36382-36394. doi: 10.18632/oncotarget.8871.
10
Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.BCR-ABL TKIs 耐药机制及治疗策略:综述。
Crit Rev Oncol Hematol. 2015 Mar;93(3):277-92. doi: 10.1016/j.critrevonc.2014.11.001. Epub 2014 Nov 13.

引用本文的文献

1
BCR::ABL1 expression in chronic myeloid leukemia cells in low oxygen is regulated by glutamine via CD36-mediated fatty acid uptake.在低氧条件下,慢性髓系白血病细胞中的BCR::ABL1表达由谷氨酰胺通过CD36介导的脂肪酸摄取来调节。
Cancer Cell Int. 2025 May 14;25(1):176. doi: 10.1186/s12935-025-03805-y.
2
The MEK5/ERK5 pathway promotes the activation of the Hedgehog/GLI signaling in melanoma cells.MEK5/ERK5信号通路促进黑色素瘤细胞中Hedgehog/GLI信号的激活。
Cell Oncol (Dordr). 2025 Feb 25. doi: 10.1007/s13402-025-01050-z.
3
Liquid Crystalline Networks Hamper the Malignancy of Cancer Cells.

本文引用的文献

1
Cap-Independent Translational Control of Carcinogenesis.癌症发生的非帽依赖性翻译控制
Front Oncol. 2016 May 25;6:128. doi: 10.3389/fonc.2016.00128. eCollection 2016.
2
Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis.脂质体硼替佐米通过破坏Sp1-BCR/ABL轴对慢性髓性白血病具有活性。
Oncotarget. 2016 Jun 14;7(24):36382-36394. doi: 10.18632/oncotarget.8871.
3
Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.重新审视肿瘤非整倍性——在分子时代ploidy 评估的地位。
液晶网络抑制癌细胞的恶性增殖。
Adv Healthc Mater. 2025 Mar;14(7):e2403607. doi: 10.1002/adhm.202403607. Epub 2025 Jan 19.
4
A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia.一种整合分子反应、毒性和血浆水平指标的新算法,用于慢性髓性白血病患者泊那替尼剂量选择
Pharmaceutics. 2024 Mar 11;16(3):383. doi: 10.3390/pharmaceutics16030383.
5
Lactate Maintains BCR/Abl Expression and Signaling in Chronic Myeloid Leukemia Cells Under Nutrient Restriction.在营养受限的情况下,乳酸维持慢性髓性白血病细胞中的 BCR/Abl 表达和信号传导。
Oncol Res. 2022 May 4;29(1):33-46. doi: 10.3727/096504022X16442289212164. Epub 2022 Feb 7.
6
Identification of an individualized autophagy prognostic index in clear cell renal cell carcinoma patients.在透明细胞肾细胞癌患者中鉴定个体化自噬预后指数。
Transl Cancer Res. 2020 Apr;9(4):2951-2961. doi: 10.21037/tcr.2020.03.06.
7
Glutamine Availability Controls BCR/Abl Protein Expression and Functional Phenotype of Chronic Myeloid Leukemia Cells Endowed with Stem/Progenitor Cell Potential.谷氨酰胺的可利用性控制具有干细胞/祖细胞潜能的慢性髓性白血病细胞的BCR/Abl蛋白表达和功能表型。
Cancers (Basel). 2021 Aug 30;13(17):4372. doi: 10.3390/cancers13174372.
8
Construction of a prognostic model based on nine immune-related genes and identification of small molecule drugs for hepatocellular carcinoma (HCC).基于九个免疫相关基因构建肝细胞癌(HCC)预后模型并鉴定小分子药物
Am J Transl Res. 2020 Sep 15;12(9):5108-5130. eCollection 2020.
9
Identification and validation of an individualized autophagy-clinical prognostic index in bladder cancer patients.膀胱癌患者个体化自噬临床预后指数的识别与验证
Onco Targets Ther. 2019 May 14;12:3695-3712. doi: 10.2147/OTT.S197676. eCollection 2019.
10
Sensitivity to imatinib of KCL22 chronic myeloid leukemia cell survival/growth and stem cell potential under glucose shortage.葡萄糖缺乏条件下KCL22慢性髓性白血病细胞存活/生长及干细胞潜能对伊马替尼的敏感性
Data Brief. 2018 Sep 19;20:1901-1904. doi: 10.1016/j.dib.2018.09.041. eCollection 2018 Oct.
Nat Rev Clin Oncol. 2016 May;13(5):291-304. doi: 10.1038/nrclinonc.2015.208. Epub 2015 Nov 24.
4
Dihydrotanshinone-I interferes with the RNA-binding activity of HuR affecting its post-transcriptional function.二氢丹参酮-I干扰HuR的RNA结合活性,影响其转录后功能。
Sci Rep. 2015 Nov 10;5:16478. doi: 10.1038/srep16478.
5
The Convergent Cancer Evolution toward a Single Cellular Destination.癌症趋同进化至单一细胞目的地。
Mol Biol Evol. 2016 Jan;33(1):4-12. doi: 10.1093/molbev/msv212. Epub 2015 Oct 13.
6
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.肾透明细胞癌对舒尼替尼产生耐药性是由于其被隔离于溶酶体中以及自噬流受到抑制。
Autophagy. 2015;11(10):1891-904. doi: 10.1080/15548627.2015.1085742.
7
Salarin C inhibits the maintenance of chronic myeloid leukemia progenitor cells.沙利霉素C抑制慢性髓性白血病祖细胞的维持。
Cell Cycle. 2015;14(19):3146-54. doi: 10.1080/15384101.2015.1078029.
8
Evolutionary determinants of cancer.癌症的进化决定因素。
Cancer Discov. 2015 Aug;5(8):806-20. doi: 10.1158/2159-8290.CD-15-0439. Epub 2015 Jul 20.
9
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.BCR/ABL1和BCR受MYC癌基因的转录调控。
Mol Cancer. 2015 Jul 16;14:132. doi: 10.1186/s12943-015-0407-0.
10
Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21.姜黄素抑制体外和体内慢性粒细胞白血病细胞的生长:miR-21外泌体处理的可能作用。
Oncotarget. 2015 Sep 8;6(26):21918-33. doi: 10.18632/oncotarget.4204.